Introduction
============

Small cell lung cancer (SCLC), which accounts for 15% of all the lung cancers, is an extremely aggressive disease with particularly poor survival rates.[@b1-ott-11-2217] Most often, the SCLC patients are categorized into the limited-stage disease (LD) or extensive-stage disease (ED) according to the Veterans Administration Lung Study Group (VALSG) staging system. Furthermore, rapid doubling time and early onset dissemination are the main characteristics of SCLC. SCLC is also characterized by initial chemosensitivity, and the first-line treatment of choice is the platinum-based regimen, usually cisplatin and etoposide.[@b2-ott-11-2217],[@b3-ott-11-2217] However, despite initial high response rates to chemotherapy, SCLC inevitably relapses. The follow-up treatment for relapsed SCLC is still a challenge. Currently, target therapies and immunotherapeutic agents are under clinical investigation.[@b4-ott-11-2217],[@b5-ott-11-2217] However, most of them have limited efficacy, and till now, there is no efficient drug approved for SCLC.[@b6-ott-11-2217] Thus, discovering novel predictive biomarkers to differentiate subtypes of SCLC for personalized treatments is the urgent need.

Epidermal growth factor receptor (*EGFR*) is a transmembrane protein that is a receptor for members of the EGF family of extracellular protein ligands. When endogenous ligands, such as EGF, bind to *EGFR*, receptor homodimerization or heterodimerization occurs at the cell surface and eventually leads to internalization of the dimerized receptor.[@b7-ott-11-2217] After receptor dimerization, the autophosphorylation of the intracytoplasmic *EGFR* tyrosine kinase domain will happen to stimulate the intracellular signal transduction cascade through several downstream pathways.[@b8-ott-11-2217] The mutations in *EGFR* exons 18, 19, and 21 in NSCLC are correlated to the response of tumors to tyrosine kinase inhibitors (TKIs). More concretely, short in-frame deletions in exon 19 and a specific point mutation in exon 21 at codon 858 are the most common *EGFR* mutations in NSCLC patients and correlated with the sensitive response of small-molecule *EGFR*-TKI.[@b3-ott-11-2217],[@b4-ott-11-2217] Whereas the T790M gatekeeper point mutation at exon 20, accounting for \~50% of all cases, is reported to be the most frequently observed resistance mechanism.[@b9-ott-11-2217] Kirsten rat sarcoma viral oncogene (*KRAS*) is a GTP-binding protein, involved in G-protein-coupled receptor signaling. The mutation status of the *KRAS* gene predicts the therapeutic efficacy of *EGFR*-TKIs in NSCLC. The patients with the wild-type *KRAS* gene may benefit from the TKI therapy.[@b10-ott-11-2217] v-raf murine sarcoma viral oncogene homolog B1 (*BRAF*) kinase links the RAS GTPase to the downstream signaling pathway of *KRAS* to phosphorylate the MEK protein directly. The mutations in the *BRAF* gene increase the kinase activity and, in turn, the constitutive stimulation of MAPK2 and MAPK3. The rate of mutation in the *BRAF* gene in NSCLC is relatively low. *BRAF* mutations could predict the effect of MEK inhibitors on NSCLC cells.[@b11-ott-11-2217] Phosphatase and tensin homolog (*PTEN*) regulates several physiological processes by inhibiting the phosphoinositide 3-kinase-v-akt murine thymoma viral oncogene homolog-mammalian target of rapamycin pathway (PI3K/AKT/mTOR pathway) through its lipid phosphatase activity. Shibata et al showed that the mutation in phosphatidylinositol-3-kinase catalytic α (*PIK3CA*) in SCLC cells renders them more sensitive to tricribine than the cells with the wild-type gene. Moreover, the SCLC cells harboring a cisplatin-resistant subclone of *PIK3CA* mutant were sensitive to tricribine similar to those without the resistance.[@b12-ott-11-2217],[@b13-ott-11-2217] Another study reported one adenocarcinoma patient with an L858R mutation in *EGFR* who displayed a robust response to erlotinib (first line of drug). The largest nodule progressed after 1 year. The core biopsy of this lesion revealed a histological transformation to SCLC that carried the L858R mutation in *EGFR* and acquired a *PIK3CA* mutation that disappeared after 6 months. Subsequently, the patient with the histological transformation to adenocarcinoma responded to a repeat course of erlotinib as the second-line course treatment.[@b14-ott-11-2217] Le et al revealed a lack of response to *EGFR* TKIs in *EGFR*-mutated de novo SCLC and large cell neuroendocrine carcinomas.[@b15-ott-11-2217] Therefore, elucidating the mutations in *EGFR*, *KRAS*, *BRAF*, *PTEN*, and *PIK3CA* in SCLC is imperative.

Two prospective studies from Taiwan and Japan reported 2.6% and 4% *EGFR* mutations, respectively.[@b16-ott-11-2217],[@b17-ott-11-2217] Surgery can be used in SCLC patients with T1-2N0M0, which is \<5% of all the SCLC patients. Thus, obtaining tumors for the detection of *EGFR* mutation in SCLC patients is rather challenging.[@b18-ott-11-2217] High-resolution melting (HRM) is a precise method, with 92% sensitivity and 100% specificity, for detecting the *EGFR* mutation using formalin-fixed tissues. This approach is also useful in predicting the clinical outcomes of NSCLC patients treated with gefitinib.[@b19-ott-11-2217] Thus, the simplicity, promptness, high sensitivity, and low rate of false-positive mutation in the HRM analysis renders it to be an optimal approach for detecting the *EGFR* mutations in circulating DNA of lung cancer patients.[@b20-ott-11-2217],[@b21-ott-11-2217] In order to distinguish the mutation status of *EGFR*, *KRAS*, *BRAF*, *PTEN*, and *PIK3CA* in SCLC patients, we used the HRM technology to assess the genes in the plasma samples.

Materials and methods
=====================

Patients
--------

From August 2012 to December 2015, 99 SCLC patients (10 females and 89 males) were prospectively assimilated in this study from the Zhejiang Cancer Hospital, People's Republic of China. The pathological diagnosis comprising of 98 conventional SCLC and 1 combined SCLC was based on the standard criteria defined by World Health Organization Classification. The mean age of patients was 60 years (range, 24--79 years). The stages as per the VALSG were as follows: LD in 44 patients and ED in 55 patients. These encompassed 14 patients who were nonsmokers, 1 patient was light, 3 were moderate, and 81 were heavy smokers. The mean pack-years was 46 (range, 0--150). The characteristics of 99 SCLC patients are summarized in [Table 1](#t1-ott-11-2217){ref-type="table"}. The study was approved by the Medical Ethical Committee of Zhejiang Cancer Hospital, and the patients signed the informed consent.

Detection of gene mutation using HRM
------------------------------------

A total of 99 blood samples were included in this study for assessing *EGFR*, *KRAS*, *BRAF*, *PTEN*, *PIK3CA* mutations. Five milliliters of vascular blood samples was withdrawn in EDTA-anticoagulation tubes. The plasma was isolated from blood samples by centrifugation at 4,000 rpm for 10 min. Then, DNA was extracted from the plasma samples using the High Pure PCR Template Preparation Kit (Roche, Mannheim, Germany) according to the manufacturer's protocol. Human genomic DNA obtained from Suzhou MicroDiag Biomedical Co., Ltd (Suzhou, People's Republic of China) was utilized as the control sample.

Eleven primer pairs were designed (Suzhou MicroDiag) to span codons 18 (G719X), 19 (del), 20 (T790M), and 21 (L858R) of the *EGFR* gene, codon 2 (G13D) of the *KRAS* gene, codon 15 (V600E) of the *BRAF* gene, codons 5 (p.R130G), 6 (p.R173C), and 8 (p.T319fs\*1) of the *PTEN* gene, and codons 9 (p.E542K) and 20 (p.H1047R) of the *PIK3CA* gene ([Table 2](#t2-ott-11-2217){ref-type="table"}).

EVA-Green (Biotium, Fremont, CA, USA) was used as the intercalating dye. The reaction mixture consisted of 5 ng plasma DNA, 10× PCR buffer, 2.5 mM MgCl~2~, 0.5 µM of each primer, 200 µM dNTP, 1U of FastStart Taq polymerase (Roche), and PCR grade water in a volume of 20 µL.

PCR cycling and HRM analysis were performed on the LightCycler^®^ 480 Real-Time PCR System (Roche Diagnostics). The amplification was carried out according to the following conditions: 1 cycle of 95°C for 5 min; 50 cycles of 95°C for 10 s, 60°C for 15 s, 72°C for 25 s. Before the HRM step, the products were heated to 95°C for 1 min and cooled to 40°C for 1 min. HRM was carried out from 65°C to 95°C, rising at 0.02°C/s with 25 acquisitions per degree.

Results
=======

By HRM, blood samples from 99 SCLC patients were sequenced to detect the genetic mutation of target genes (*EGFR*, *KRAS*, *BRAF*, *PIK3CA*, and *PTEN*). Consequently, target-site mutation was detected in 15 patients. Among them, these mutations of 12 patients were mutually exclusive, and the remaining 3 patients carried multiple mutations. As shown in [Table 3](#t3-ott-11-2217){ref-type="table"}, the number of patients who carried *EGFR*/*KRAS*/*BRAF*/*PIK3CA*/*PTEN* mutation was 9/5/1/1/0, respectively. In detail, *EGFR* 18 (G719X) mutation in 5 (5.05%) patients, *EGFR* 19 (del) mutation in 2 (2.02%) patients, *EGFR* 20 (T790M) mutation in 3 (3.03%) patients, *EGFR* 21 (L858R) mutation in 2 (2.02%) patients, *KRAS* 2 (G13D) mutation in 5 (5.05%) patients, *BRAF* 15 (V600E) mutation in 1 (1.01%) patient ([Figure 1](#f1-ott-11-2217){ref-type="fig"}), *PIK3CA* 9 (E542K) mutation in 1 (1.01%) patient ([Figure 2](#f2-ott-11-2217){ref-type="fig"}), and no mutations of *PTEN* 5 (R130G), *PTEN* 6 (R173C), *PTEN* 8 (T319fs\*1), and *PIK3CA* 20 (H1047R) were found. Three patients with multiple mutations, one patient harboring *EGFR* 18 (G719X) and *EGFR* 19 (del) mutations ([Figure 3](#f3-ott-11-2217){ref-type="fig"}), one patient harboring *EGFR* 20 (T790M) and *EGFR* 21 (L858R) ([Figure 4](#f4-ott-11-2217){ref-type="fig"}), and another patient harboring *EGFR* 18 (G719X), *EGFR* 20 (T790M), and *KRAS* 2 (G13D) mutations ([Figure 5](#f5-ott-11-2217){ref-type="fig"}) were identified. The nine patients (one female and eight males) harboring *EGFR* mutations expressed a mean age of 59 years (range, 48--71 years). The stages were as follows: LD in four patients and ED in five patients. One patient was a nonsmoker, and eight were heavy smokers.

Discussion
==========

In the present study, the percentage of *EGFR* mutations in SCLC plasma is higher than from the tumor tissue in previous reports.[@b16-ott-11-2217]--[@b18-ott-11-2217],[@b22-ott-11-2217] The *EGFR* mutation from tumor tissue can only reflect the mutation status of the tissue that is evaluated; heterogeneity occurs widely in different parts of the tissue in the same patient.[@b23-ott-11-2217] The *EGFR* mutation in plasma may originate from all the tumor tissues of the whole body. The patients with *EGFR*-mutated SCLC tended to be females, nonsmokers, and in SCLC including "conventional SCLC and combined SCLC". Combined SCLC is SCLC containing discrete areas of non-mall cell morphologic components.[@b25-ott-11-2217]--[@b27-ott-11-2217] A study revealed 28% of the SCLC patients who underwent surgical resection exhibited combined SCLC,[@b28-ott-11-2217] while other reports demonstrated that combined SCLC accounted for 1%--3.2% of all the SCLC cases who received no surgery.[@b29-ott-11-2217],[@b30-ott-11-2217] Surgery can be considered only in T1-2N0M0 SCLC patients; however, these cases have been reported to account for \<5% of all the SCLC patients.[@b18-ott-11-2217] None of our SCLC patients underwent surgery. The diagnosis of combined SCLC using biopsy or needle puncture is extremely arduous. Twenty to thirty percent of our SCLC patients may have combined SCLC, and we could not diagnose combined SCLC through small specimens obtained from biopsy or needle puncture. Heterogeneity can also explain the double mutation of *EGFR* in plasma of the same patient. SCLC developing in association with adenocarcinoma, either synchronously or metachronously, seemed to correlate with the *EGFR* mutation, irrespective of TKI usage.[@b31-ott-11-2217] The *EGFR* mutation may easily occur in SCLC combined adenocarcinoma than in SCLC combined with other NSCLC complements.[@b25-ott-11-2217] Because of the specific involvement of *EGFR* mutations in adenocarcinoma, it is suggested that the SCLCs may have developed from preexisting adenocarcinomas.[@b17-ott-11-2217] As we all know, *EGFR* activating mutations, including exon 19 deletions or an exon 21 Leu858Arg mutation, present favorable outcome after treating with *EGFR* TKI.[@b32-ott-11-2217],[@b33-ott-11-2217] In SCLC, several studies have also performed a similar research. A 72-year-old woman with *EGFR* exon 19 mutation (del E746-A750) utilized gefitinib as the treatment method.[@b34-ott-11-2217] After 3 weeks, CT was performed, which revealed marked regression of both the primary lung tumor and the metastatic liver tumor. The histological examination of this patient was confirmed as SCLC. Another clinical report also revealed a pronounced positive effect of gefitinib in a patient with metastatic SCLC.[@b35-ott-11-2217] Second-generation inhibitors, including afatinib, dacomitinib, and neratinib, have been verified markedly with high efficacy in NSCLC patients with the G719X mutation.[@b36-ott-11-2217],[@b37-ott-11-2217] Based on our research, *EGFR* 18 (G719X) is the most common *EGFR* mutation of SCLC in the current report, which is different from lung adenocarcinoma with the main mutations *EGFR* 19 (del) and *EGFR* 21 (L858R).[@b38-ott-11-2217],[@b39-ott-11-2217] Thus, we speculated that G719X might be a promising mutation for treatment. Bordi et al reported that all the SCLC cases harbored wild-type *BRAF*, *KRAS*, platelet-derived growth factor receptor alpha, and c-KIT (data available for 82 patients) genes.[@b24-ott-11-2217] Other studies reveal \~2%--5% *KRAS* mutations in patients with SCLC.[@b40-ott-11-2217],[@b41-ott-11-2217] Our study also confirmed that fewer mutations of *KRAS* and *BRAF* in SCLC patients might be correlated with the resistance to TKI in NSCLC in the background of these mutations.[@b10-ott-11-2217],[@b42-ott-11-2217]--[@b45-ott-11-2217] In our study, *EGFR* and *KRAS* mutations are detected in one SCLC patient. Le et al demonstrated the lack of response to *EGFR* TKIs in one *EGFR*-mutated de novo SCLC patient, which might be attributed to the *KRAS* or *BRAF* mutation; however, the underlying mechanism is yet to be elucidated.[@b15-ott-11-2217] Selumetinib is a tight-binding, noncompetitive inhibitor of MEK 1 and 2 that acts downstream of *KRAS* and is administered orally. Recently, a randomized, Phase II trial involving selumetinib plus docetaxel improved the progression-free survival when compared with docetaxel alone in patients who were treated previously for advanced NSCLC harboring the *KRAS* mutant.[@b46-ott-11-2217] Furthermore, the role of *BRAF* mutation in NSCLC and the optimal treatment are yet to be elucidated. The regression of intracranial disease by Robinson et al indicated that vemurafenib traversed the blood--brain barrier and efficaciously treated the brain metastasis in lung cancer patients with a V600E mutation in *BRAF* gene.[@b47-ott-11-2217] Thus, selumetinib and vemurafenib in SCLC with *KRAS* or *BRAF* mutation can be explored prospectively.

The PI3K/AKT/mTOR pathway plays a unique role with respect to genomic alterations in SCLC.[@b48-ott-11-2217] The inactivated *PTEN* advances the SCLC in a genetic mouse model, thereby suggesting that a subset of patients with SCLC can be treated by targeting the *PTEN* pathway.[@b49-ott-11-2217] Li et al indicated that adenovirus-mediated *PTEN* together with cisplatin could be an efficient novel therapeutic modality for the treatment of patients with SCLC.[@b50-ott-11-2217] Tricribine is a small molecule inhibitor of AKT signaling. It is localized downstream of *PIK3CA* and inhibited the growth and colony formation of "*PIK3CA*-addicted" cells significantly. Moreover, the SCLC cells harboring the mutated *PIK3CA* are more sensitive to tricribine than the wild-type cells. On the other hand, the cisplatin-resistant subclones of *PIK3CA*-mutant SCLC cells exhibited sensitivity to tricribine similar to those with *PIK3CA*. The anti-AKT molecular therapy was found to be efficient for a subgroup of SCLC with *PIK3CA* mutation.[@b51-ott-11-2217] PF-4989216 is a potential cancer therapeutic candidate for the treatment of SCLC patients with *PIK3CA* mutation and without *PTEN* loss.[@b52-ott-11-2217] Reverse transcription-polymerase chain reaction and direct sequencing technology were employed for the detection of *PIK3CA* mutation in 14 cases of patients with SCLC, assimilated retrospectively, who underwent surgical treatment at the Zhejiang Cancer Hospital from 2002 to 2010. The analysis did not reveal any mutations in exons 9 and 20 of the *PIK3CA* gene in the tumor tissue of patients with SCLC.[@b53-ott-11-2217] In the current study, one patient presented the *PIK3CA* mutation. The percentage of *PIK3CA* mutations is similar to *PTEN*: \~5%.[@b27-ott-11-2217],[@b40-ott-11-2217],[@b48-ott-11-2217] Sasaki et al and Schmid et al[@b43-ott-11-2217],[@b54-ott-11-2217] established the synergistic effects of the combination therapy of Erlotinib and RAD001 with respect to cell viability, proliferation, and autophagy.

Conclusion
==========

Our study revealed the mutation of the targeted genes from SCLC. The mutations in *KRAS*, *BRAF*, and *PIK3CA* are rare in patients with SCLC, and the mutation in *EGFR* might differ from that in lung adenocarcinoma. The experimental results laid the foundation for better understanding of the mutation characteristics of SCLC and the following research on the application of targeted drugs.
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![The patient was a 62-year-old male ED-SCLC with heavy smoking. Result of *BRAF* (V600E) mutation. (**A**) Melting peaks. The blue line represents the melting curve of standard product, and the red line represents the melting curve of genome DNA from SCLC patients. All the red lines and blue lines of the figures below represent the same meaning. (**B**) Normalized and temperature-shifted difference plot.\
**Abbreviations:** ED, extensive-stage disease; SCLC, small cell lung cancer.](ott-11-2217Fig1){#f1-ott-11-2217}

![The patient was a 62-year-old male ED-SCLC with heavy smoking. Result of *PIK3CA* 9 (E542K) mutation. (**A**) Melting peaks. (**B**) Normalized and temperature-shifted difference plot. The blue line represents the melting curve of standard product, and the red line represents the melting curve of genome DNA from SCLC patients. The meaning of red line and blue line on each figure is the same.\
**Abbreviations:** ED, extensive-stage disease; *PIK3CA*, phosphatidylinositol-3-kinase catalytic α; SCLC, small cell lung cancer.](ott-11-2217Fig2){#f2-ott-11-2217}

![The patient was a 55-year-old male ED-SCLC with heavy smoking. (**A**) Melting peaks of *EGFR* 18 (G719X) mutation. (**B**) Normalized and temperature-shifted difference plot of *EGFR* 18 (G719X) mutation. (**C**) Melting peaks of *EGFR* 19 (del) mutation. (**D**) Normalized and temperature-shifted difference plot of *EGFR* 19 (del) mutation.\
**Abbreviations:** ED, extensive-stage disease; *EGFR*, epidermal growth factor receptor; SCLC, small cell lung cancer.](ott-11-2217Fig3){#f3-ott-11-2217}

![The patient was a 59-year-old male ED-SCLC with heavy smoking. (**A**) Melting peaks of *EGFR* 20 (T790M) mutation. (**B**) Normalized and temperature-shifted difference plot of *EGFR* 20 (T790M) mutation. (**C**) Melting peaks of *EGFR* 21 (L858R) mutation. (**D**) Normalized and temperature-shifted difference plot of *EGFR* 21 (L858R) mutation.\
**Abbreviations:** ED, extensive stage disease; *EGFR*, epidermal growth factor receptor; SCLC, small cell lung cancer.](ott-11-2217Fig4){#f4-ott-11-2217}

![The patient was a 51-year-old male ED-SCLC with heavy smoking. (**A**) Melting peaks of *EGFR* 18 (G719X) mutation. (**B**) Normalized and temperature-shifted difference plot of *EGFR* 18 (G719X). (**C**) Melting peaks of *EGFR* 20 (T790M) mutation. (**D**) Normalized and temperature-shifted difference plot of *EGFR* 20 (T790M) mutation. (**E**) Melting peaks of *KRAS* 2 (G13D) mutation. (**F**) Normalized and temperature-shifted difference plot of *KRAS* 2 (G13D) mutation.\
**Abbreviations:** ED, extensive-stage disease; *EGFR*, epidermal growth factor receptor; *KRAS*, Kirsten rat sarcoma viral oncogene; SCLC, small cell lung cancer.](ott-11-2217Fig5){#f5-ott-11-2217}

###### 

Patient characteristics

  Characteristic   Number of patients
  ---------------- --------------------
  Total            99
  Gender           
   Male            89
   Female          10
  Smoking status   
   Never           14
   Light           1
   Moderate        3
   Heavy           81
  Stage            
   LD              44
   ED              55

**Notes:** Smoking status was evaluated on the PY, and PY were calculated by multiplying the number of packs of cigarettes smoked per day by the number of years the person has smoked. Never represents patients who never smoked light represents PY≤10; moderate represents PY\>10 and \<20; heavy represents PY≥20.

**Abbreviations:** ED, extensive-stage disease; LD, limited-stage disease; PY, pack years.

###### 

Primer sequences for amplifying target genes

  Gene              Exon                              Site                              Primer sequences                  
  ----------------- --------------------------------- --------------------------------- --------------------------------- ---------------------------------
  *EGFR*            18                                G719A                             **F**:TAAGTGTCTGGAAGTCAACTGGGGA   **R**:ACATTGTTTCACACTTATTATCTCT
  G719S             **F**:ATTGCCCTCAACACAGTGGAGCGAA   **R**:TTGAGGGCAATGAGGACATAACCAG                                     
  G719C             **F**:TCCCCGCCTCGCCGCCAACGCCACA   **R**:CCACCTCACAGTTATTGAACATCCT                                     
  19                E746_A750del(1)                   **F**:GCCTTGTGCTCCCCCGAGGGCTGCT   **R**:CCAGCAGCCCTCGGGGGAGCACAAG   
  E746_A750del(2)   **F**:GAAAACAACACCCTGGTCTGGAAGT   **R**:ACTTCCAGACCAGGGTGTTGTTTTC                                     
  L747_P753\>S      **F**:GAAGCAACATCTCCGAAAGCCAACA   **R**:ATTTCCTTGTTGGCTTTCGGAGATG                                     
  E746_T751\>I      **F**:AGCAACATCTCCGAAAGCCAACAAG   **R**:TCCTTGTTGGCTTTCGGAGATGTTG                                     
  E746_T751del      **F**:CTCACTCTCCATAAATGCTACGAAT   **R**:CCAGAGGAGGAGTATGTGTGAAGGA                                     
  E746_T751\>A      **F**:GAACTGCCAGAAACTGACCAAAATC   **R**:GGCAGACCAGGCAGTCGCTCTCCCG                                     
  E746_S752\>A      **F**:CCCTTCGGCTGCCTCCTGGACTATG   **R**:ACATAGTCCAGGAGGCAGCCGAAGG                                     
  E746_S752\>V      **F**:TGGGCAACCCCGAGTATCTCAACAC   **R**:CAGGTGGGCTGGACAGTGTTGAGAT                                     
  E746_S752\>D      **F**:AGCCATCACCCCAACCCCCCAAAAT   **R**:AGAAAACTATCTTCCATAAGTAACA                                     
  L747_A750\>P      **F**:TGGGCAACCCCGAGTATCTCAACAC   **R**:ACAGGTGGGCTGGACAGTGTTGAGA                                     
  L747_T751\>Q      **F**:ATTTTCAGCCTACAGTTATGTTCAG   **R**:GTGACTGAACATAACTGTAGGCTGA                                     
  L747_E749del      **F**:TCAGCCTACAGTTATGTTCAGTCAC   **R**:TGTGTGACTGAACATAACTGTAGGC                                     
  L747_T751del      **F**:CTTGACTGAGGACAGCATAGACGAC   **R**:TTTTGGGAACGGACTGGTTTATGTA                                     
  L747_S752del      **F**:AGCAGAGACCCACACTACCAGGACC   **R**:TGTGGGGGTCCTGGTAGTGTGGGTC                                     
  L747_A750\>P      **F**:TCCTAGGTTCAAATCTGGAAGTGGT   **R**:TTCCAGATTTGAACCTAGGACCTCC                                     
  L747_P753\>Q      **F**:TTATTACTCAACCTTCAACCCAGAC   **R**:GTCTGGGTTGAAGGTTGAGTAATAA                                     
  L747_T751\>S      **F**:ATTGGTACAGATGAGACTTCAGAAA   **R**:TTTTCTGAAGTCTCATCTGTACCAA                                     
  L747_T751del      **F**:CATGGCATAGGGTTCGAATATCTGA   **R**:GAACCCTATGCCATGGGGATAAGTG                                     
  L747_T751\>P      **F**:ATTGGTACAGATGAGACTTCAGAAA   **R**:CTTTTCTGAAGTCTCATCTGTACCA                                     
  20                T790M                             **F**:CTGCCCCCAAACCCCCTCCTTACGC   **R**:TGTGTGACAAAGCGTAAGGAGGGGG   
  21                L858R                             **F**:CAAAGAGTATATGTTCCCTCCAGGT   **R**:AAGCGTAAGGAGGGGGTTTGGGGGC   
  *KRAS*            2                                 G13D                              **F**:CAATCCACCAGCTAACCGCCTGAAA   **R**:ATGCACATGTTTAAGTCTATTTCAG
  *BRAF*            15                                V600E                             **F**:ATAAACCTGAGATAATGGCATGGCT   **R**:CCTCCAGCCATGCCATTATCTCAGG
  *PTEN*            5                                 R130G                             **F**:AGCAACCAGGACCGAGACCCACACT   **R**:TCCTCGGAGTTGTTGGCTTATGTTG
  6                 R173C                             **F**:ATCTGGAAGTCCTAGGTTCAATGGT   **R**:CCAGTATGTGTAGAGGAGGGAAGGA   
  8                 T319fs^\*^1                       **F**:TACCTCAACCTTTATTACAACCCAG   **R**:GGCCAGTCGCTAGACCAGGCTCCCG   
  *PIK3CA*          9                                 E542K                             **F**:ATAGACTTCAGAAATGGTACAGATG   **R**:ACATGCAGCAGTCCAGGAGCGAAGG
  20                H1047R                            **F**:CTATCGGTTCGAATGAATGGCATAG   **R**:CAGGCAGTGTTGATGGGCTGGAGAT   

**Abbreviations:** *BRAF*, v-raf murine sarcoma viral oncogene homolog B1; *EGFR*, epidermal growth factor receptor; *KRAS*, Kirsten rat sarcoma viral oncogene; *PIK3CA*, phosphatidylinositol-3-kinase catalytic α; *PTEN*, phosphatase and tensin homolog.

###### 

Results of patients with mutated genes by HRM

  --------------------------------------------------------------------------------------------------
  Patient number   Stage   Gender   Age   Smoking history   Mutation      Melting temperature (°C)
  ---------------- ------- -------- ----- ----------------- ------------- --------------------------
  1                LD      Female   71    No                *EGFR*-E19    83

  6                ED      Male     55    Heavy             *EGFR*-E18\   87.3\
                                                            *EGFR*-E19    83.8

  8                ED      Male     50    Moderate          *KRAS*-E2     83.4

  14               ED      Male     59    Heavy             *EGFR*-E20\   90.5\
                                                            *EGFR*-E21    88.9

  20               LD      Male     46    Heavy             *KRAS*-E2     83.2

  21               ED      Male     79    No                *KRAS*-E2     83.9

  30               ED      Male     66    Heavy             *EGFR*-E18    88

  32               ED      Male     51    Heavy             *EGFR*-E18\   87.6\
                                                            *EGFR*-E20\   90.8\
                                                            *KRAS*-E2     83.8

  42               ED      Male     62    Heavy             *BRAF*-E15    82.3

  43               LD      Female   67    No                *KRAS*-E2     83

  48               LD      Male     62    Heavy             *EGFR*-E18    86.9

  51               ED      Male     59    Heavy             *EGFR*-E18    86.4

  54               LD      Male     57    Heavy             *EGFR*-E20    90.3

  80               LD      Male     48    Heavy             *EGFR*-E21    83.8

  83               ED      Male     52    Heavy             *PIK3CA*-E9   80.8
  --------------------------------------------------------------------------------------------------

**Notes:** Smoking status was evaluated on the PY, and PY were calculated by multiplying the number of packs of cigarettes smoked per day by the number of years the person has smoked. Never represents never smoked patient; light represents PY≤10; moderate represents PY\>10 and \<20; heavy represents PY≥20.

**Abbreviations:** ED, extensive-stage disease; *EGFR*, epidermal growth factor receptor; HRM, high-resolution melting; *KRAS*, Kirsten rat sarcoma viral oncogene; LD, limited-stage disease; *PIK3CA*, phosphatidylinositol-3-kinase catalytic α; PY, pack years.
